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Abstract.  We have investigated the ability of exoge- 
nous transforming growth factor-/3 (TGF-/3) to induce 
osteogenesis and chondrogenesis,  critical events in 
both bone formation and fracture healing.  Daily injec- 
tions of TGF-/$1 or 2 into the subperiosteal region of 
newborn rat femurs resulted in localized intramem- 
branous bone formation and chondrogenesis.  After 
cessation of the injections, endochondral  ossification 
occurred, resulting  in replacement of cartilage with 
bone. Gene expression of type II collagen and  im- 
munolocalization of types I and II collagen were de- 
tected within the TGF-/~-induced cartilage and bone. 
Moreover, injection of TGF-/32  stimulated synthesis of 
TGF-/31 in chondrocytes and osteoblasts within the 
newly induced bone and cartilage,  suggesting positive 
autoregulation of TGF-~.  TGF-/32 was more active in 
vivo than  TGF-/31, stimulating  formation of a  mass that 
was on the average 375 % larger at a comparable dose 
(p <  0.001).  With either TGF-/~ isoform, the dose of 
the growth factor determined which type of tissue 
formed, so that the ratio of cartilage formation to in- 
tramembranous bone formation decreased as the dose 
was lowered. For TGF-/31, reducing the daily dose 
from 200 to 20 ng decreased the cartilage/intramem- 
branous bone formation ratio from 3.57 to zero (p < 
0.001).  With TGF-/32,  the same dose change decreased 
the ratio from 3.71 to 0.28 (p <  0.001).  These data 
demonstrate that mesenchymal precursor cells in the 
periosteum are stimulated by TGF-/3 to proliferate and 
differentiate,  as occurs in embryologic bone formation 
and early fracture healing. 
T 
HE  most  abundant  sources  of the  25,000-mol  wt 
homodimeric peptide,  transforming  growth  factor-/3 
(TGF-/~)',  are  bone  and  platelets  (1,  45,  48).  This 
multifunctional  peptide has a broad range of cellular activi- 
ties including  control of the proliferation  and expression of 
the differentiated  phenotype of several cell types specific to 
bone, among them mesenchymal  precursor cells, chondro- 
cytes, osteoblasts, and osteoclasts (1, 8, 9, 45, 46, 47, 48). 
TGF-/~ exists in several distinct homodimeric forms, two of 
which, TGF-/3s I and 2, have been isolated from bone in ap- 
proximately  a 4:1 ratio (10, ll, 25, 45, 46, 47, 48). In vitro 
studies have suggested that both TGF-/~s 1 and 2 may regulate 
osteogenesis and  chondrogenesis  by affecting  replication, 
gene expression,  and structural  protein synthesis  in nearly 
all the cell types involved in bone formation  (4, 7, 35, 45). 
Moreover, in vivo studies based on both immunohistochemi- 
cal staining  and on in situ hybridization  have demonstrated 
synthesis of TGF-/$ by both chondrocytes and osteoblasts (15, 
21, 41) and accumulation  of TGF-/$ in a model of endochon- 
dral ossification  (5). 
TGF-/3 plays a central  role in regulating  the complex cas- 
cade of cellular events involved in healing soft tissues, a pro- 
cess initiated by release of the peptide after platelet degranu- 
i. Abbreviations  used in this paper: GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; TGE  transforming growth factor. 
lation  (1, 2).  In addition,  exogenous  application  of TGF-/3 
stimulates  formation of granulation  tissue typical of a heal- 
ing response (34) and  strengthens  incisional  wounds (32). 
The present study was designed to determine if TGF-/~ might 
play a similar role in stimulating the formation of new carti- 
lage and bone, as occurs during  the healing  response after 
a bone fracture.  We have investigated whether TGF-/~, when 
injected into uninjured bone, can initiate chondrogenesis  and 
osteogenesis,  analogous  to the induction  of granulation  tis- 
sue observed after subcutaneous injection of the peptide into 
uninjured  soft tissue sites (34). Our results show that either 
TGF-/$1 or 2,  injected  subperiosteally into growing  bone, 
initiates a self-propagated  tissue response leading to forma- 
tion of new bone, similar to the response seen in fracture 
healing.  TGF-/~ alone initiated  a cellular cascade of events 
that included the stimulation of proliferation,  differentiation, 
and extracellular  matrix synthesis in target periosteal mesen- 
chymal cells, chondrocytes, and osteoblasts, as occurs dur- 
ing physiological  chondrogenesis  and osteogenesis. 
Materials and Methods 
Animal Procedures 
A total of 88 newborn Long Evans rats, ages 2-4 d, were divided into 6 
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Growth factor  Days  Days  Number of 
Group  injected  Dose  injected  harvested  animals 
I  TGF-/31  200 ng  14  3,  5,  8,  15, 21,  35  18 
II  TGP-/31  20 ng  14  3,  5,  8,  15, 21, 35  18 
M  TGF-/T2  200 ng  14  3,  5,  8,  15, 21, 35  18 
IV  TGF-/32  20 ng  14  3,  5,  8,  15, 21, 35  18 
V  BSA  100 ug  14  8,  15  6 
VI  TGF-/32  200 ng  14  15  10 
Figure 1. Subperiosteal injection technique. Using a dull 27-gauge 
needle, microinjections were directed into the subperiosteal region 
of the anterior surface of the rat femur. The technique was perfected 
by injecting dye until injections could be consistently reproduced. 
Verification of growth factor application to the subperiosteal region 
was confirmed with immunohistologic localization by anti-TGF-/31 
antibodies (data not shown). 
experimental groups (Table I). Animals in groups I, II, III, and IV received 
daily  10-t~l injections  of 200 ng TGF-131, 20 ng TGF-/~I, 200 ng TGF-~2, 
or 20 ng TGF-/32, respectively, into the subperiosteum of the anterior, mid- 
diaphyseal  portion of their uninjured right femur for 14 consecutive  days 
(Fig.  1); the TGF-/3 was dissolved in PBS, pH 7.4. The left femur was in- 
jected in a similar fashion with PBS alone, allowing each animal to serve 
as its own control. Animals were harvested for histology  either during the 
injection phase of the experiment, or at different time points after receiving 
14 injections.  Animals in group V received seven daily injections  of 1% 
BSA. Animals in group VI received  14 daily injections of 200 ng TGF-132; 
on day 15, both legs were used for radiographic and histologic analysis. The 
porcine TGF-~I and TGF-132 used in this study were purchased from R&D 
Systems  Inc.  (Minneapolis, MN). 
Histological Analysis 
Tissues were fixed for 2-3 d in 10% neutral buffered formalin, 2 d in Bouin's 
solution, followed by decalcification in a 10% acetic acid, 0.85% NaCI,  10% 
formalin  solution  (AFS)  (26).  This protocol resulted in adequate decal- 
cification,  without loss  of antigenic  sites for immunohistologic studies. 
Sagittal and cross sections were obtained in groups I, II, M, and IV, while 
the specimens  in the remaining groups were all sectioned  sagittally. Paraf- 
fin-embedded specimens were stained with hematoxylin and eosin, or Mas- 
son's Trichrome (American Histology  Labs, Frederick, MD). 
Quantitative Analysis and Statistics 
Photomicrographs and radiographs were quantified  using a computerized 
image analysis program. Photomicrographs, at a 10× magnification,  were 
taken of the histologic sections described above and scanned on an Apple 
digital scanner (n =  87).  In a similar fashion,  radiographs of femurs that 
received TGF-/3 injections,  were also scanned (n =  10). The computerized 
images were analyzed for cross-sectional area on a Macintosh lh computer 
using an image analysis program (Image Version 1.20, Wayne Rasband, Na- 
tional Institutes of Health,  Bethesda MD).  Areas of induced mass,  in- 
tramembranous bone, cartilage,  and endochondral bone were measured  in 
triplicate and averaged for each histological  image. For quantification,  the 
induced mass was defined as the area of periosteal proliferation, intramem- 
branous bone, endochondral bone, cartilage, and remodeled trabecular 
bone, but not fibrous tissue. For the determination of"percent cartilage for- 
mation" the areas of cartilage and endochondral bone were added together. 
This calculation is valid since endochondral bone must form from cartilagi- 
nous matrix, in contrast to intramembranous bone which forms without a 
cartilaginous matrix. 
In determining the effect of TGF-/31 and 2  on total mass formation, 
significance was calculated  using the SAS general linear model for an un- 
balanced, three-way ANOVA in which the three factors were growth factor, 
dose, and day (n =  87) (43).  The analysis was done on transposed data to 
stabilize the variance (43). In determining the effect of the dose of TGF-BI 
or 2 on the stimulation of either cartilage or intramembranous bone forma- 
tion, significance was determined as above, with a three-way ANOVA, and 
confirmed with a two-tail  t test (n =  72). 
lmmunohistochemistry 
Immunohistochemistry was performed on paraffin-embedded  sections us- 
ing an avidin-biotin  peroxidase detection system (Vector Laboratories, Inc., 
Burlingame, CA), as described by Heine et al. (15). Two polyclonal antibod- 
ies to TGF-#I (anti-LC and anti-CC) were made in rabbits to the same syn- 
thetic peptide corresponding to the amino-terminal 30 amino acids of TGF- 
81 (12, 13). These antibodies are specific for TGF-BI and do not recognize 
TGF-/32 or 3. The anti-LC antibody recognizes intraeellular TOF-13, while 
the anti-CC antibody recognizes  extrecellular peptide (13, 50).  Serial sec- 
tions of the treated tissue were stained with a polyclonal  antibody against 
type I collagen (3) and a monoclonal antibody against type II collagen (44) 
after limited hyaluronidase digestion. Sections were countersta~ned with May 
Grunwald and Giemsa stains. Serial sections developed  after omission of 
Figure 2. Radiographic analysis. Limbs were radiographed after receiving 14 daily injections of either TGF-/T2 (200 rig) or PBS. (,4) Radio- 
graphic appearance of a large calcified mass located on the anterior aspect of the right femur injected with TGF-/T2; (B) normal appearance 
of a  control limb injected with PBS. 
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ing. Negative  controls consisted of parallel sections incubated with com- 
parable dilutions of rabbit, mouse, or goat IgG preimmune serum. 
RNA Extraction and Northern Blotting 
15 newborn Long  Evans rats received daily injections of 200 ng TGF-#I 
as described above. After two, four,  and seven  injections, five  animals were 
killed, and the region of the femur and overlying  soft tissue that had been 
exposed to the TGF-B was dissected and pooled. RNA was extracted by a 
technique modified for bone and cartilage (27), denatured, and electropho- 
resed in agarose  gels. Northern  hybridization  was Carried  out using standard 
techniques (27) with cDNA probes for alpha-l-(ll)procollagen  and glyceral- 
dehyde-3-phosphate dehydrogenase (GAPDH) (23, 52). Autoradiographs 
were made by exposing nylon membranes (Hybond-N)  to radiographic film. 
Results 
Development of a Model for Subperiosteal  Injection of 
Long Bones 
To determine the in vivo effects of TGF-13 on skeletal tissue, 
we developed a model in which exogenous growth factors are 
delivered  into the  subperiosteal  region of newborn  rat  fe- 
murs  (Fig.  1).  The periosteum  is comprised of two tissue 
layers:  an  outer  fibroblast  layer  and  an  inner  region  of 
undifferentiated mesenchymal cells (14, 30). Extensive stud- 
ies of fracture healing have demonstrated  that this  mesen- 
chymal cell population is the likely source of chondrocyte 
and osteoblast precursor cells (51). Exposure of this popula- 
tion of cells to exogenous TGF-~ provides an ideal model in 
which the effects of TGF-~3 on cell proliferation, differentia- 
tion,  and  extracellular  matrix  synthesis  can be  studied  in 
vivo. 
Radiographic Detection of  Bone Formation Resulting 
From Subperiosteai  Injection of TGF-~2 
To survey the net effect of TGF-/32 on new bone formation, 
10 newborn Long Evans rats received 14 daily 200-ng injec- 
tions of TGF-/32 into the subperiosteal aspect of their right 
femur.  The animals were killed on day 15 for radiographic 
analysis (Fig. 2). In all 10 animals, a large calcified mass was 
detected at the site of injection of TGF-/32 (Fig.  2 A), with 
no apparent deviation from the normal on the PBS-injected 
side  (Fig.  2  B).  Although the injections  were  initially  di- 
rected at the mid-diaphaseal  region of the bone, dispropor- 
tional elongation of the growing femur distally results in the 
proximal position of the mass by the time of x-ray. The size 
of the induced calcified mass was measured using the inte- 
gral density of its radiographic image and then reported as 
Figure 3. Histology of  femurs after two and four daily subperiosteal 
injections  of TGF-/T2. Daily injections  of 200 ng of TGF-ff2 were 
given. (A) Rat killed on day 3, after two TGF-ff2 injections;  mesen- 
chymal cell proliferation (MP) was evident both within  the peri- 
osteum above cortical bone (CB) and along the endosteal surface 
(arrow); also noted is the fibrous tissue (FT) penetrating the muscle 
fibers at the site of the injection.  (B) Rat killed on day 5, after four 
200-ng TGF-/~2 injections; at the injection site a newly formed car- 
tilaginous  matrix (CT) is flanked  by regions of intramembranous 
bone (IB) while the opposing cortex (arrow) appears  unaffected; 
(C) on higher magnification,  chondrocytes (CC) can be identified 
within the cartilage,  as can osteoblasts  lining bone spicules  (OB). 
A well-demarcated  border separates  these regions of chondrogene- 
sis and osteogenesis  (/arge arrow). (BM) bone marrow; (arrow- 
head) injection  site.  Bar,  100 #m. 
Joyce et al. TGF-13:  Initiation of Osteogenesis and Chondrogenesis  2197 Figure 4. Cross-sectional histology of femurs after four TGF-/32  subperiosteal injections. Daily 200-ng injections were given. Rats were 
killed on day 5, after 4 injections; (,4) cross section, at the site of injection, of a femur injected with TGF-/32, demonstrating the localized 
extent of cartilage (CT) and intramembranous bone formation (IB) at the site of injection, with the opposing cortex appearing unaffected; 
(B) cross section at the site of injection of a control femur that received PBS, demonstrating a normal histological appearance. Bar, 250/~m. 
a fraction of the whole femur. The mean induced mass was 
determined to comprise 24.7% of the femur (SD  =  6.2%). 
TGF-I~  Initiates Chondrogenesis  and Osteogenesis in 
Injected Limbs 
Having demonstrated a potent effect of TGF-~ on the induc- 
tion of new bone formation in this model system, we under- 
took a complete study of the dose and time-dependence of 
the response to "I'GF-/3,  based on detailed examination of the 
histology of the induced tissue.  Daily subperiosteal injec- 
tions of either TGF-~l or TGF-~2 into the rat femur resulted 
in a  complex and reproducible pattern of tissue formation 
and differentiation that included subperiosteal proliferation, 
intramembranous bone formation, and chondrogenesis. In 
contrast, either 7 or 14 daily injections of 10 ~tg/#l BSA or 
14  injections  of PBS  resulted in  only minimal  periosteal 
proliferation at the site of injection in 4 of 88 control sections 
examined  (Fig.  4  B).  Since the  most profound tissue  re- 
sponse was seen with the 200-ng TGF-/Y2 dose, this experi- 
ment (Table I, group III) has been used to illustrate the tem- 
poral sequence of events induced by injection of TGF-~. 
Periosteal Proliferation. Mesenchymal cell proliferation 
within the inner cambrial layer of the periosteum was seen 
after two 200-ng injections of TGF-/~2,  resulting in expan- 
sion from its resting, three cell layers, to >8-cell layers thick- 
ness (Fig.  3 A, MP).  The outer fibrous layer of the peri- 
osteum remained intact except for mechanical disruption at 
the injection site. As evidence of proliferation, mitotic figures 
were seen in a small number of the cells within the enlarging 
tissue mass. The distribution of responding tissue was spe- 
cific. The most intense proliferation was at the injection site, 
with a minimal response laterally, and no effect  on the oppos- 
ing cortex. Periosteal proliferation remained evident through- 
out the 14 d of TGF-/32 injections and returned to its resting 
state within  1 wk of discontinuing the TGF-/3. 
Chondrogenesis.  Chondrocytes were identified within a 
cartilaginous matrix after four injections of 200 ng TGF-/32 
(Figs. 3 B and 4 A). Cartilage, lacking structural organiza- 
tion, formed at the site of injection and enlarged with 7 injec- 
tions. At this time, chondrocytes appeared immature with a 
compact cytoplasm and  small  lacuna.  Cartilage  not only 
formed above the cortex, but also appeared to replace under- 
lying cortical bone.  Numerous osteoclasts were identified 
within regions where cortical bone was being resorbed, pos- 
sibly facilitating the continued invasion of cartilage into the 
underlying cortex. After 14 injections, the size of the car- 
tilaginous mass had increased several fold and an organiza- 
tional pattern had emerged (Fig. 5). Hypertrophic chondro- 
cytes were seen near the cortical border of the mass, while 
smaller immature chondrocytes were seen in the vicinity of 
the proliferating mesenchymal cells nearer the periosteum 
(Figs. 5, B and C,  CT and CC).  Throughout the period of 
TGF-/3 injections, the cartilaginous mass was surrounded by 
areas of intramembranous bone formation. 
Intraraembranous Bone Formation. New bone was de- 
tected in the region lateral to the induced cartilage after four 
injections of TGF-/32 (Figs. 3, B and C, and 4 A). Without 
evidence for a prior cartilage matrix, it must be assumed that 
The Journal of Cell Biology, Volume 110,  1990  2198 Figure 5. Histology of femurs after 14 daily subperiosteal injections of TGF-B2. Rat killed on day 15, after 14 daily injections of 200 
ng TGF-B2; (A) low power photomicrograph demonstrating a large cartilaginous mass (CT) at the site of injection that is flanked by in- 
tramembranous bone (IB). The response is localized to the injected cortex, with a normal appearing opposite cortex (CB). (B) Enlargement 
of A emphasizing the sharp demarcation between active chondrogenesis (CT) and osteogenesis (IB). (C and D) High power photomicro- 
graphs demonstrating a maturation progression of  cells from a primitive mesenchymal appearance (MC) to a chondrocytic phenotype (CC) 
in a cartilaginous matrix or a maturational progression of cells from a mesenchymal appearance (MC) to an osteoblastic phenotype (OB) 
lining newly formed bone spicules. (Arrowhead) Injection site; PO, intact periosteum.  Bar, 100 #m. 
these newly formed bony spicules,  lined with osteoblasts, 
arose directly from the underlying cortical bone by the pro- 
cess of intramembranous bone formation (Fig.  3 C, OB). 
The mass of intramembranous bone increased in size through- 
out the 14 d of TGF-B2 injections (Fig. 5 B, IB).  Early in 
this bone formation process, osteoblasts had a rounded ap- 
pearance, indicative of active matrix synthesis. As injections 
continued, cellular synthetic activity decreased, as evidenced 
by a flattening of their cytoplasm. Throughout this region, 
mature osteoblasts were seen near the bony cortex, while im- 
mature osteoblasts could be identified closer to the prolifer- 
ating mesenchymal cells of  the periosteum (Fig. 5 D, MCand 
OB). 
Cessation of TGF-B Injections 
Results in Endochondral Ossification and 
New Bone Remodeling 
To determine the fate of the newly formed cartilage induced 
following the TGF-fl2 injections, animals were killed 1 and 
3 wk after TGF-fl injections had been stopped.  Histologic 
analysis demonstrated that the cartilage was first replaced 
with bone by the process of endochondral ossification, and 
that the bone formed by intramembranous and endochondral 
ossification was then remodeled into thickened cortical bone. 
Endochondral Ossification. The large cartilaginous mass 
that formed as a  result of TGF-~ injection underwent en- 
Joyce et al.  TGF-~5:  Initiation of Osteogenesis and Chondrogenesis  2199 Figure 6. Histology of femurs after cessation of TGF-82 injections.  Femurs were analyzed 1 and 3 wk after the completion of the series 
of 14 daily injections  of 200 ng TGF-/~2. (A) Low power photomicrograph of a femur injected  with TGF-~2, on day 21, demonstrating 
the development of  an endochondral ossification  front (EO) where cartilage (CT) is replaced with endochondral bone (EB). Box is enlarged 
in C. (B and C) High power views of  the endochondral ossification  front demonstrating hypertrophic chondrocytes (HC), osteoblasts  (OB) 
newly synthesized  osteoid (arrows),  and vascular  invasion (CAP). Box in C is enlarged in B. (D) Photomicrograph demonstrating bone 
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Figure 7.  Quantitation of cartilage and bone formation resulting 
from subperiosteal injection of 200 ng TGF-¢2. TGF-B2 (200 ng) 
was injected daily. Specimens were harvested for histologic analy- 
sis  as  indicated.  Sections were photographed  and  subsequently 
digitized on an Apple scanner. The resulting digital images were 
quantified for (a) size of total induced tissue mass (not including 
fibrous tissue); (b) area of intramembranous bone formation; (c) 
area of cartilage formation; and (d) area of endochondral bone for- 
mation. On harvest day 35,  the mass was comprised of induced 
trabecular bone. 
dochondral ossification once the TGF-~ treatment was dis- 
continued (Fig. 6, A-D). Within 1 wk of stopping TGF-~ in- 
jections (day 21 of the experiment) 50 % of the cartilaginous 
mass  had been replaced with bone (Fig.  6  B).  Histologic 
analysis demonstrated that during this process the chondro- 
cytes  developed  an  organized  appearance  similar  to  the 
growth plate with resting above proliferating above hyper- 
trophic chondrocytes (Fig. 6,  C and D).  Columns of these 
chondrocytes extended perpendicular to the long axis of the 
bone. Mineralization of the longitudinal septa between col- 
umns of cells coincided with chondrocyte hypertrophy (Fig. 
6 B, HC). Newly formed endochondral bone had the classic 
mixed spicule appearance that resulted from the deposition 
ofosteoid (new bone matrix) onto the calcified cartilaginous 
matrix (Fig.  6,  B  and  C,  EB).  Endochondral ossification 
continued and 3 wk after the last TGF-/~2 injection (day 35 
of the experiment) the cartilaginous mass was completely re- 
placed with bone (Fig.  6 E,  TB). 
Remodeling.  New bone, arising by either endochondral or 
intramembranous ossification, and existing cortical bone, was 
continually being remodeled (Fig. 6 E, TB). Histological ex- 
amination suggested active remodeling as evidenced by the 
presence of  multinucleated osteoclasts resorbing bone within 
the irregular surfaces of excavation sites along trabecular 
bone (Fig. 6 F, OC). This process was followed by the ap- 
pearance ofosteoid-synthesizing osteoblasts (Fig. 6 F, OB), 
resulting finally in the formation of thickened cortical bone. 
Histological sections were analyzed quantitatively through- 
out the course of the TGF-/32 injection study. Areas of total 
tissue formation and specific types of tissue formation (in- 
tramembranous  bone,  cartilage,  and  endochondral  bone) 
were measured. The results of this analysis are summarized 
in Fig. 7. The total area of tissue formation increased to 61.7 
mm  ~ during the injection phase of the experiment, and then 
decreased to  18.6 mm  2 3  wk after the last injection.  The 
composition of the tissue that comprised this mass was also 
found to vary over the course of the experiment. 
Comparison of the Effects of TGF-ff2 and TGF-~I on 
Bone Formation In Vivo 
TGF-/31 was found to induce the formation of cartilage and 
bone in a similar, yet not identical, sequence to that just de- 
scribed for TGF-~2 (Fig. 8). Comparison of TGF-/31 to TGF- 
/32, at either the 200-ng/d or the 20-ng/d dose, demonstrated 
a difference in the amount of induced tissue formed (Fig. 9 
a). TGF-/32 was found to be more active than TGF-/~I, stimu- 
lating formation of a  mass  that was  on the average 375 % 
larger at the comparable dose (p < 0.001; n  =  87). Although 
much larger masses of bone and cartilage were formed fol- 
lowing TGF-~2 injections, the ratio of cartilage to intramem- 
branous bone formation within those masses  was  not sig- 
nificantly different (Fig. 9 b). At the 200-ng/d dose, this ratio 
was 3.57 for TGF-~I and 3.71 for TGF-/32 (p =  0.046), while 
at the 20-ng/d dose, the ratio was 0.0 for TGF-/31 and 0.28 
for "I'GF-/32 (p  =  0.049). 
The formation of cartilage, at the immediate site of injec- 
tion, and intramembranous bone, lateral to the site of injec- 
tion, was a consistent finding (Fig. 8). This spatial relation- 
ship could be explained by assuming that TGF-/3 diffused 
from the injection site with a decreasing concentration gra- 
dient, and that the concentration of TGF-/3, and not the iso- 
form, determined the pathway of tissue formation into either 
cartilage or bone. This hypothesis was tested by repeating the 
injection sequence for both TGF-/31 and TGF-/32 at a lower, 
formation by two different processes, endochondrai ossification (EB) and intramembranous ossification (IB), and the well-demarcated bor- 
der between these two types of  bone. (E) Low power photomicrograph of  a femur on day 35, 3 wk after completion of 14 TGF-B2  injections, 
demonstrating remodeling of both newly formed bone and existing cortical bone into thickened trabecular bone (TB); (F) high power 
view of regions of osteoclastic bone resorption (OC) and osteoid deposition (arrow) by osteoblasts (OB) on day 35. (BM), bone marrow; 
(arrowhead) injection site; (PO) intact periosteum; (FT) fibrous tissue. Bar, (B and F) 50 #m;  (A, C, D, and E) 100 #m. 
Joyce ¢t al. TGF-[3:  Initiation of Osteogenesis and Chondrogenesis  2201 Figure 8. Histological comparison of high and low dose subperiosteal injections of TGF-/~2 and TGF-BI. Animals received 14 daily injec- 
tions of either TGF-BI or TGF-B2 at two doses (200 or 20 ng) and were killed 1 wk later. (A) TGF-B2,200-ng dose, a large cartilaginous 
mass (CT) at the site of injection, is flanked by a small region of intramembranous bone formation (IB). In contrast is (B) TGF-B2, 20-ng 
dose.  Although a smaller mass of cartilage (CT) is evident at the injection site, it is flanked by an increased area of intramembranous 
bone formation (IB). (C) TGF-/~I, 200-rig dose,  a relatively large area of cartilage (CT), at the injection site is flanked by a region of 
intramembranous  bone (IB). (D) TGF-~I, 20 ng dose, a small area of intramembranous  bone (IB) is seen at the injection site. There is 
no detectable cartilage.  Bar, 250 #m. 
20-ng/d, dose (Fig. 9).  For both isoforms there was a dose 
dependent increase in the amount of tissue formed (Fig. 9 a; 
p  <  0.001, n  =  87). Whereas, the relative proportion of in- 
tramembranous bone formation compared to cartilage for- 
mation increased as the dose was lowered (Fig.  9  b).  For 
TGF-~I, decreasing the daily dose from 200 to 20 ng de- 
creased cartilage formation from 48.2% to zero (p <  0.001; 
n  =  72)  and  increased  intramembranous bone formation 
from 13.5%  to 47.0%  (p <  0.001,  n  =  72);  with TGF-/ff2, 
the  same dose change decreased cartilage formation from 
61.7%  to  14.5%  (p <  0.001,  n  ~-  72) and increased intra- 
membranous bone formation from  16.6%  to  51.4%  (p < 
0.001,  n  =  72). 
TGF-ff2-induced Matrix Contains both Type I 
and ~pe H Collagen 
To further define the composition of the matrix induced by 
injection  of TGF-/~2,  we  stained  sections  throughout  the 
study with antitype I and antitype II collagen antibodies (Fig. 
10).  Antitype II collagen antibodies selectively stained the 
matrix surrounding proliferative chondrocytes, but failed to 
stain the matrix surrounding the hypertrophic chondrocytes 
(Fig.  10 A, PC). Type I collagen was localized throughout 
the  entire cartilaginous  mass; however, staining  was most 
striking around the hypertrophic chondrocytes (Fig.  10 B, 
HC). In addition, type I collagen antibodies stained osteoid 
within the newly formed bone spicules, in areas of both in- 
tramembranous and endochondral  ossification  (Fig.  10 B, 
arrow). There was no collagen type II staining in areas of 
bone formation. 
TGF-~I treatment increased expression of mRNA for type 
II collagen, compared to the control limbs, after two 200-ng 
injections. This increase in type II collagen expression was 
not sustained, however, as message levels were identical to 
that of control limbs after both four and seven daily injec- 
tions of TGF-/31 (Fig.  11). The expression of GAPDH was 
not affected by the TGF-B1  injections. 
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Figure 9. Quantitative comparison of TGF-~31 and TGF-•2  at two 
doses. (a) Rat femurs were treated with either TGF-/~I or TGF-32 
at both 200 and 20 ng daily dose. Animals were killed, sagittal 
histology was performed, and the area (in mm  2) of induced tissue 
formation was quantified as described. Both TGF-~I (p < 0.001) and 
TGF-/32 (p < 0.001) stimulated tissue mass formation (defined as 
periosteum, cartilage, intramembranous bone, endochondral bone, 
and new trabecular bone, but not fibrous tissue) in a dose dependent 
fashion. Compared to TGF-I~I,  TGF-/32  stimulated the formation of 
a larger mass at both the 200-ng dose and the 20 ng doses (p < 
0.001, n  =  87). (b) Decreasing the TGF-~I dose from 200 to 20 
ng/d resulted in a decreased percent of cartilage formation (p < 
0.001) and an increased percent of intramembranous bone forma- 
tion (p < 0.001). Likewise, for TGF-/32 decreasing the dose from 
200 to 20 ng/d resulted in a decrease in cartilage formation (p < 
0.001) and an increase in intramembranous bone formation (p < 
0.001). At either the 200- or 20-ng dose, TGF-/32  stimulated a larger 
percent of cartilage formation (p = 0.016,  p = 0.010, respectively), 
but no significant difference was found in the percent of intramem- 
branous bone formation. (For the determination of "percent carti- 
lage formation; the areas of cartilage and endochondral bone were 
added together. This calculation is valid since endochondral bone 
must form from cartilaginous matrix,  in contrast  to intramem- 
branous bone that forms without a cartilaginous matrix.) 
Induction of TGF-B1 Synthesis by Treatment 
with TGF-~2 
Since  autocrine  induction  of TGF-fl  synthesis  had  been 
demonstrated in an osteoblastic cell line in vitro (35, 52), we 
investigated whether synthesis of TGF-B might be induced 
within the tissue as a result of the TGF-~ injections (Fig. 12). 
Using anti-TGF-~l (LC) and anti-TGF-~ (CC) antibodies to 
stain the bone and cartilage formed as a result of TGF-~2 
injections,  we found intraceUular staining  of proliferating 
chondrocytes and osteoblasts with the LC antibodies and ex- 
tracellular staining for TGF-/~I within the matrix surround- 
ing hypertrophic chondrocytes using the CC antibodies. This 
pattern is identical to that observed in growth plate chondro- 
cytes of young rats (20) and in developing vertebrae of a 15- 
d-old mouse embryo (13). Western blot analysis has demon- 
strated no cross-reactivity between the TGF-/5'I antibodies 
used in this study and the native TGF-/32 peptide injected 
into these animals (12,  13).  Since the animals had been in- 
jected with TGF-/~2, the observed staining cannot represent 
the exogenous TGF-/~2, but rather demonstrates induction of 
TGF-~I synthesis by TGF-/~2 in both chondrocytes and os- 
teoblasts in vivo. 
Discussion 
In this study, we have shown for the first time that TGF-8 in- 
jected subperiosteally into the femur of young rats can initi- 
ate a complex series of events resulting ultimately in new 
bone formation. Our results suggest that not only can TGF-~ 
induce the differentiation of periosteal mesenchymal cells 
into osteoblasts and chondrocytes but that it can also stimu- 
late these cells to proliferate and synthesize the extracellular 
matrix proteins characteristic of bone and  cartilage.  The 
mechanism by which TGF-/~ promotes chondrogenesis and 
osteogenesis is unknown; however, it is likely to involve the 
possibilities that TGF-/~ may be chemotactic for cells in- 
volved in these processes, or even less directly, that TGF-/3 
may induce cells to secrete other peptides with these activi- 
ties (22, 33, 54). Moreover, the demonstrated autostimula- 
tory effect of TGF-/3 injections is certainly an important as- 
pect of its action (Fig.  12). 
It has been shown previously that TGF-~ is capable of 
influencing the proliferation and phenotypic expression of 
osteoblasts, chondrocytes, and primitive mesenchymal cells 
in vitro (4, 35,  37, 38, 45). Immunohistoehemical staining 
and in situ hybridization have demonstrated that TGF-# is 
synthesized by chondrocytes and osteoblasts during embryo- 
genesis  (15, 40,  fracture healing  (21),  and  in  an  in  vivo 
model of endochondral ossification (5). Our histochemical 
analysis of the effects of TGF-D on periosteal mesenchymal 
cells in vivo corroborate in vitro observations demonstrating 
both  that  TGF-#  induces  differentiation of mesenchymal 
cells into a chondrocytic phenotype (37, 45) and that TGF-/~ 
stimulates  osteoblast proliferation and  synthesis of type I 
collagen (6, 7, 35). The present study demonstrates that con- 
tinued injections of TGF-~ result in increasing amounts of 
cartilage formation; however, it is unclear whether this re- 
sults from the proliferation of  chondrocytes, or the differenti- 
ation (or recruitment) of mesenchymal cells. Nevertheless, 
we found that when TGF-B injections were discontinued, the 
cartilaginous mass no longer enlarged and was replaced by 
bone. 
Joyce et al.  TGF-[3:  Initiation of Osteogenesis and Chondrogenesis  2203 Figure 10. Immunohistology with antitypes I and II collagen antibodies. Femurs received 14 daily injections of 200-rig TGF-/Y2, and rats 
were killed I wk later. (A) Antibodies to type II collagen stain the extracellular matrix surrounding proliferating chondrocytes (PC) within 
the cartilage.  Antibodies fail to detect type II collagen surrounding hypertrophic chondrocytes (HC), and endochondral bone (EB). (B) 
Antibodies to type I collagen stain hypertrophic  chondrocytes (HC) and their  surrounding extracellular  matrix.  Type I collagen is also 
present within newly synthesized osteoid (arrow) in the region of the endochondral  ossification front (EO). Bars,  100 tLm. 
With either isoform of TGF-~, the dose of the growth fac- 
tor determined which type of tissue formed, such that the ra- 
tio of cartilage formation to intramembranous bone forma- 
tion decreased as the dose was lowered. At high doses (200 
ng),  and  at  the  immediate  injection  site,  differentiation 
proceeded in the direction of chondrogenesis;  at the lower 
dose (20 ng), and at the higher dose in regions further from 
the immediate injection  site (i.e.,  where there would be a 
lower concentration of the peptide), there was relatively less 
chondrogenesis and more osteoblast differentiation resulting 
in intramembranous bone formation (Figs. 8 and 9). These 
data suggest that the local concentration of TGF-# may deter- 
mine the path of differentiation of the periosteal mesenchymal 
cells into either chondrocytes or osteoblasts. 
Although a  much larger mass of bone and cartilage was 
formed in response to injection of TGF-/32 (at both the 200- 
ng and 20-ng doses), the ratio of bone to cartilage within that 
mass was not significantly different than in the smaller mass 
stimulated by TGF-ffl. These data suggest that TGF-~I and 2 
stimulate periosteal mesenchymal cell differentiation through 
a similar mechanism, while affecting the ultimate amount of 
tissue formation through a different mechanism. The possi- 
bility that TGF-~ and TGF-/32 act similarly to affect mesen- 
chymal differentiation pathways is supported by in vitro data 
Figure 11. Northern blot analysis for expression of type II procolla- 
gen mRNA. The right leg of newborn rats received daily injections 
of 200-ng TGF-ffl and the left leg control injections of PBS. Five 
animals were killed on days 3, 5, or 8, after two, four or seven injec- 
tions, respectively, and the injection sites were dissected and pooled 
for RNA extraction.  5/tg of total RNA was resolved on a  1.5% 
agarose-formaldehyde gel,  transferred  to nylon membranes, and 
probed  for alpha-l-(II)procollagen  and  GAPDH as described  in 
Materials  and Methods. 
The Journal of Cell Biology, Volume 110, 1990  2204 Figure 12. Immunohistology  with anti-TGF-~l(LC) and (CC) antibodies. Femurs received 14 daily injections of 200 ng TGF-/~2 and were 
harvested at 8, 15, or 21 d after the initial injection. (A) Photomicrograph of an early cartilaginous mass, overlying cortical bone (CB), 
induced by TGF-B2 injections (day 8). Anti-TGF-/5'I(I-30)-LC  antibody stained TGF-/31 in proliferating chondrocytes (PC). (B) Pho- 
tomicrograph of the mass induced by TGF-/T2 (day 15) in the region of periosteal mesenchymai cell proliferation (MP) and underlying 
intramembranous  bone formation (IB). Anti-TGF-/~I(I-30)-LC  antibody stained TGF-/51 in mesenchymal  cells and osteoblasts (OB, arrows) 
throughout the induced tissue mass. (C and D) Photomicrographs on day 21, the cartilaginous region in C contains proliferating chondro- 
cytes (PC)  that stained intensely  with the anti-TGF-/31(I-30)-LC  antibody (arrow). At the endochondral ossification  front (EO) hypertrophic 
chondrocytes (HC) are stained with the anti-TGF-/5'I(I-30)-CC antibody. Bars, 100 #m. 
(45).  Although these two isoforms of TGF-fl are only 72 % 
identical, they are interchangeable in most in vitro assays, in- 
cluding several with bone cells (7, 35). In addition, Noda et 
al. demonstrated that both TGF-/$1 and 2 act similarly by in- 
ducing formation of periosteal woven bone in newborn rat 
parietal bones (28). In contrast, a selective response pattern 
has been  observed  in  certain systems. These  include the 
selective action of TGF-/31 in inhibition of growth of en- 
dothelial cells (18) and the selective action of TGF-/~2 in in- 
duction of mesoderm in explants of amphibian ectoderm 
(36).  The present data suggest that not only is TGF-/Y2 a 
more active stimulator of osteogenesis and chondrogenesis 
than TGF-/31 in vivo, but that both isoforms of TGF-/~ share 
the ability to influence the pathway of tissue differentiation 
into bone or cartilage by a dose dependent action. 
Type I and II collagen were localized to specific regions 
of the newly formed bone and cartilage induced by the injec- 
tions of TGF-/32. Type I collagen is the principal extracellu- 
lar matrix protein of bone, and has been immunolocalized 
around hypertrophic chondrocytes and in mineralized carti- 
lage (16, 53).  In addition, it is found in areas of new bone 
formation at the growth plate and in the fracture callus (21a, 
42). Type II collagen, the major extracellular matrix protein 
in cartilage, is synthesized in the growth plate in regions of 
proliferating chondrocytes, but not hypertrophic chondro- 
cytes (24, 40).  From the perspective of the localization of 
these major matrix proteins, it appears that the mechanism 
of bone and cartilage formation stimulated by TGF-/$ closely 
parallels the normal physiologic process. 
There are many published studies of the effects of TGF-/~ 
on chondrocytes, osteoblasts, and other mesenchymal cells 
in vitro.  Although these studies have shed light on many 
functions of TGF-/$, they are at times conflicting and confus- 
ing. For example, TGF-/$ has been shown to be both a stimu- 
lator and inhibitor of osteoblast proliferation (7, 35), and to 
be able to either increase or decrease type II collagen synthe- 
sis  in  chondrocytes (39).  These  contradictions,  in  many 
cases, can be explained by differences in serum concentra- 
tion, source and age of the cells, and the precise phenotypic 
description of the cells under study. In addition, the apparent 
function of  TGF-fl can be altered by other growth factors act- 
ing in combination with it (17, 45, 48), or by systemic hor- 
Joyce et al.  TGF-~: Initiation of Osteogenesis and Chondrogenesis  2205 mones (29, 31). In fact, the well documented multifunction- 
ality of TGF-~ action (48) precludes prediction of its in vivo 
activities based solely on in vitro experiments. 
These data add to the growing body of evidence on the in 
vivo activity of TGF-/i The ability of TGF-~, in nanogram 
quantities, to stimulate formation of granulation  tissue, ac- 
celerate the accumulation of protein, collagen,  and DNA, 
and  increase  wound  strength  has  been  demonstrated  in 
numerous rat subcutaneous tissue models (32,  34, 49).  In 
these studies, TGF-3 did not stimulate bone or cartilage for- 
mation. This would support the crucial role that the subperi- 
osteal mesenchymal cell population plays in our experiments 
where the predominant response to TGF-3 is the induction 
of bone and cartilage.  TGF-/31 or TGF-32 injected onto the 
periosteum of newborn rat parietal bones results  in the for- 
mation of woven bone, without evidence of cartilage forma- 
tion (28). In light of the data presented here, where cartilage 
formation was stimulated by both TGF-31 and 2, it would ap- 
pear that the mesenchymal cell populations in calvaria  and 
long bones respond differently to TGF-/3. 
The present study on the effects of TGF-/3 on bone and car- 
tilage formation adds  increasing support for a role for the 
peptide in fracture healing. TGF-/3 is released by platelets (1, 
2) at the time of fracture  and is synthesized by both osteo- 
blasts and chondrocytes at specific times, in specific regions, 
during the fracture healing process (21). Injection of TGF-/3 
into  the  subperiosteum  of an  uninjured  bone  mimics  the 
platelet release of TGF-/3 in the same region, when a bone 
is fractured.  The data presented here show that the effect of 
TGF-3 on the periosteum is first to stimulate the prolifera- 
tion of mesenchymal cells that then differentiate  into chon- 
drocytes and osteoblasts, The net result of continued TGF-3 
injection was the formation of a callus with central cartilage 
and lateral intramembranous bone; the endochondral  replace- 
ment of the cartilage, and the remodeling into cortical bone 
after cessation  of the  TGF-3  treatments.  These processes 
correlate  with those described  in normal  fracture  healing 
(19). The ability to initiate such a response by exogenous ap- 
plication of TGF-3 suggests many important therapeutic uses 
for the peptide in fracture  repair and bone grafting. 
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